Market Place
Sourcing Support
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
26 Mar 2024 //
GLOBENEWSWIRE
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
AgeX keeps defying time to survive multiyear cash crunch
15 Aug 2023 //
FIERCE BIOTECH
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
BUSINESSWIRE
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
24 Jul 2023 //
BUSINESSWIRE
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
21 Jul 2023 //
BUSINESSWIRE
AgeX Therapeutics Announces Appeal of NYSE American Determination
23 May 2023 //
BUSINESSWIRE
AgeX Therapeutics Reports First Quarter 2023 Financial Results
12 May 2023 //
BUSINESSWIRE
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
31 Mar 2023 //
BUSINESSWIRE
AgeX Receives Extension of Time to Attain Compliance With Stock Exchange
25 Nov 2022 //
BUSINESSWIRE
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Time may be running out for anti-aging biotech AgeX
15 Aug 2022 //
FIERCEBIOTECH
AgeX Therapeutics Reports First Quarter 2022 Financial Results
13 May 2022 //
BUSINESSWIRE
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
23 Nov 2021 //
BUSINESSWIRE
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
12 Nov 2021 //
BUSINESSWIRE
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
BUSINESSWIRE
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
23 Jul 2021 //
BUSINESSWIRE
AgeX to Collaborate with The Ohio State University to Generate Proof-of-Concept
10 Mar 2021 //
BUSINESSWIRE
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
02 Mar 2021 //
BUSINESSWIRE
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
02 Mar 2021 //
BIOSPACE
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem B
28 Oct 2020 //
BIOSPACE
AgeX Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology IMS001
27 Oct 2020 //
BUSINESSWIRE
AgeX Therapeutics Reports First Quarter 2020 Financial Results Provides Business
08 Oct 2020 //
PRESSRELEASE
AgeX & Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement
16 Jun 2020 //
BUSINESSWIRE
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
05 Jun 2020 //
BUSINESSWIRE
AgeX Therapeutics & ImStem Biotechnology Sign Non-Binding LOI IMS001
02 Jun 2020 //
BUSINESSWIRE
AgeX & Sernova to Collaborate to Engineer Universal Immune Cell Therapies
29 May 2020 //
BUSINESSWIRE
AgeX`s Licensee ImStem Biotechnology Announces FDA has Lifted the Hold
20 Mar 2020 //
BUSINESSWIRE
